Immunoglobulin light and heavy chain amyloidosis AL/AH: Renal pathology and differential diagnosis

Contributions to Nephrology

Volumn 153, Issue , 2007, Pages 135-155

  Picken, Maria M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; BIOPSY; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOLOGY; KIDNEY; METABOLISM; PARAPROTEINEMIA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEINURIA; REVIEW; ULTRASTRUCTURE;

AMYLOID; AMYLOIDOSIS; BIOPSY; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY; PARAPROTEINEMIAS; PROTEINURIA;

EID: 33751536338     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000096765     Document Type: Review

References (85)

1. Westermark P, Benson MD, Buxbaum JN, et al: Amyloid: toward terminology clarification. Amyloid 2005;12:1-4.
2. Falk RH, Skinner M: The systemic amyloidoses: an overview. Adv Intern Med 2000;45:107-137.
3. Picken MM: The changing concepts of amyloid. Arch Pathol Lab Med 2001;25:38-43.
4. Röcken C, Sletten K: Amyloid in surgical pathology. Virchows Arch 2003;443:3-16.
5. Obici L, Perfetti V, Palladini G, et al: Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;1753:11-22.
6. Tirzaman O, Wahner-Roedler DL, Malek RS, et al: Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc 2000;75:1264-1268.
7. Gertz MA, Lacy MQ, Dispenzieri A: Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 2004;18:17-37.
8. Dember LM: Emerging treatment approaches for systemic amyloidoses. Kid Int 2005;68:1377-1390.
9. Gertz MA, Merlini G, Treon SP: Amyloidosis and Waldenström's macroglobulinemia. Hematology 2004;1:257-282.
10. Mai HL, Sheikh-Hamad D, Herrera GA, et al: Immunoglobulin heavy chain can be amyloidogenic: morphologic characterization, including immunoelectron microscopy. Am J Surg Pathol 2003;27:541-545.
11. Copeland JN, Kouides PA, Grieff M, et al: Metachronous development of nonamyloidotic lambda light chain deposition disease and IgG heavy chain amyloidosis in the same patient. Am J Surg Pathol 2003;27:1477-1482.
12. Yazaki M, Fushimi T, Tokuda T, et al: A patient with severe renal amyloidosis associated with an immunoglobulin gamma-heavy chain fragment. Am J Kidney Dis 2004;43e:23-28.
13. Tuglular S, Yalcinkaya F, Paydas S, et al: A retrospective analysis for etiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 2002;17:2003-2005.
14. Röcken C, Shakespeare A: Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002;440:111-122.
15. Stojanov S, Kastner DL: Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005;17:586-599.
16. Haagsma EB, Hawkins PN, Benson MD, et al: Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families. Amyloid 2004;11:44-49.
17. Kang HG, Bybee A, Ha IS, et al: Hereditary amyloidosis in early childhood associated with a novel insertion-deletion (indel) in the fibrinogen Aalpha chain gene. Kidney Int 2005;68:1994-1998.
18. Gregorini G, Izzi C, Obici L, et al: Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol 2005;16:3680-3686.
19. Magy N, Liepnieks JJ, Yazaki M, et al: Renal transplantation for apolipoprotein AII amyloidosis. Amyloid 2003;10:224-228.
20. Granel B, Valleix S, Serratrice J, et al: Lysozyme amyloidosis. Report of 4 cases and a review of the literature. Medicine 2006;85:66-73.
21. Connors LH, Prokayeva T, Akar H, et al: Familial amyloidosis: recent novel and rare mutations in a clinical population; in Grateau G, Kyle RA, Skinner M (eds): Amyloid and Amyloidosis. Boca Raton, London, New York, Washington DC, CRC Press, 2005, pp 360-362.
22. Lachmann HJ, Booth DR, Booth SE, et al: Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-1791.
23. Hawkins PN: Hereditary systemic amyloidoses with renal involvement. J Nephrol 2003;16:443-448.
24. Westermark P, Bergstrom J, Solomon A, et al: Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 2003;1:48-54.
25. Picken MM, Leya F, Picken RN: Wild type transthyretin-derived senile systemic amyloidosis with limited proteolytic digestion of the monomer: clinico-pathologic studies with DNA and amyloid protein characterization; in Grateau G, Kyle RA, Skinner M (eds): Amyloid and Amyloidosis. Boca Raton, London, New York, Washington DC, CRC Press, 2005, pp 466-467.
26. Haas M, Meehan SM, Karrison TG, et al: Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997;30:621-631.
27. Herrera GA: Renal manifestations in plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory. Ann Diagn Pathol 2000;4:174-200.
28. Markowitz GS: Dysproteinemia and the kidney. Adv Anat Pathol 2004;11:49-63.
29. Gu X, Herrera GA: Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch Pathol Lab Med 2006;130:165-169.
30. Jacquot C, Saint-Andre JP, Touchard G, et al: Association of systemic light-chain deposition disease and amyloidosis: a report of three patients with renal involvement. Clin Nephrol 1985;24:93-98.
31. Kirkpatrick CJ, Curry A, Galle J, et al: Systemic kappa light chain deposition and amyloidosis in multiple myeloma: novel morphological observations. Histopathology 1986;10:1065-1076.
32. Picken MM, Frangione B, Barlogie B, et al: Light chain deposition disease derived from the V kappa light chain subgroup. Biochemical characterization. Am J Pathol 1989;134:749-754.
33. Lin J, Markowitz GS, Valeri AM, et al: Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001;12:1482-1492.
34. Komatsuda A, Maki N, Wakui H, et al: Development of systemic lambda-light chain amyloidosis in a patient with gamma-heavy chain deposition disease during long-term follow-up. Nephrol Dial Transplant 2005;20:434-437.
35. Copeland JN, Kouides PA, Grieff M, et al: Metachronous development of nonamyloidogenic lambda light chain deposition disease and IgG heavy chain amyloidosis in the same patient. Am J Surg Pathol 2003;27:1472-1482.
36. Kapur U, Fresco R, Picken MM: Expanding the spectrum of proximal tubulopathy associated with plasma cell dysplasia: an appraisal of five patients from a single institution. Mod Pathol 2006;19(suppl 1):263.
37. Merlini G, Westermark P: The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004;255:159-178.
38. Sanders PW: Management of paraproteinemic renal disease. Curr Opin Nephrol Hypertens 2005;14:97-103.
39. Gertz MA, Comenzo R, Falk RH, et al: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319-328.
40. Herrera GA, Joseph L, Gu X, et al: Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasias. Arch Pathol Lab Med 2004;128:875-879.
41. Ekclund L: Radiologic findings in renal amyloidosis. AJR Am J Roentgenol 1977;129:851-853.
42. Elghetany MT, Saleem A, Barr K: The Congo red stain revisited. Ann Clin Lab Sci 1989;19:190-195.
43. Churukian CJ: Improved Puchtler's Congo red method for demonstrating amyloid. J Histotechnol 2000;23:139-141.
44. Linke RP: Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence. Virchows Arch 2000;436:439-448.
45. Krebs MR, Bromley EH, Donald AM: The binding of thioflavin-T to amyloid fibrils: localization and implications. J Struct Biol 2005;149:30-37.
46. Tagouri YM, Sanders PW, Picken MM, et al: In vitro AL-amyloid formation by rat and human mesangial cells. Lab Invest 1996;74:290-302.
47. Shiiki H, Shimokama T, Yoshikawa Y, et al: Renal amyloidosis. Correlation between morphology, chemical types of amyloid and clinical features. Virchows Arch A Pathol Anat Histopathol 1988;412:197-204.
48. Looi LM, Cheah PL: Histomorphological patterns of renal amyloidosis: a correlation between histology and chemical type of amyloidosis. Human Pathol 1997;28:847-849.
49. Sasatomi Y, Kiyoshi Y, Uesugi N, et al: Prognosis of renal amyloidosis: a clinicopathological study using cluster analysis. Nephron 2001;87:42-49.
50. Nagata M, Shimokama T, Harada A, et al: Glomerular crescents in renal amyloidosis: an epiphenomenon or distinct pathology? Pathol Int 2001;51:179-186.
51. Schafernak KT, Chugh SS, Kanwar YS: Co-existent crescentic glomerulonephritis and renal amyloidosis: a case report and literature review. J Nephrol 2005;18:616-622.
52. Falck HM, Tornroth T, Wegelius O: Predominantly vascular amyloid deposition in the kidney in patients with minimal or no proteinuria. Clin Nephrol 1983;19:137-142.
53. Pettersson T, Antilla P, Tornroth T: Renal glomerular AL and vascular AA amyloidosis in a patient with ankylosing spondylitis; in Grateau G, Kyle RA, Skinner M (eds): Amyloid and Amyloidosis. Boca Raton, London, New York, Washington DC, CRC Press, 2005, pp 284-285.
54. Wetzel R: Ideas of order for amyloid fibril structure. Structure 2002;10:1031-1036.
55. Howell D, Gu X, Herrera GA: Organized deposits and look-alikes. Ultrastruct Pathol 2003;27:295-312.
56. Veeramachaneni R, Gu X, Herrera GA: Atypical amyloidosis: diagnostic challenges and the role of immunoelectron microscopy in diagnosis. Ultrastruct Pathol 2004;28:75-82.
57. Nishi S, Ogino S, Maruyama Y, et al: Electron-microscopic and immunohistochemical study of beta-2-microglobulin-related amyloidosis. Nephron 1990;56:357-363.
58. Keeling J, Herrera GA: Matrix metalloproteinase and mesangial cell remodeling in light chain-related glomerular damage. Kidney Int 2005;68:1590-1603.
59. Bridoux F, Hugue V, Coldefy O, et al: Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 2002;62:1764-1775.
60. Hvala A, Ferluga D, Vizjak A, et al: Fibrillary noncongophilic renal and extrarenal deposits: a report on 10 cases. Ultrastruct Pathol 2003;27:341-347.
61. Nabarra B, Larquet E, Diemert MC, et al: Unusual IgM fibrillar deposits in glomerulonephritis: ultrastructural and diffraction studies in a case report. Hum Pathol 2003;34:1350-1354.
62. Rosenstock JL, Markowitz GS, Valeri AM, et al: Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int 2003;63:2450-2462.
63. Palladini G, Obici L, Merlini G: Hereditary amyloidosis. N Engl J Med 2002;347:1206-1207.
64. Comenzo RL, Zhou P, Fleisher M, et al: Seeking confidence in the diagnosis of systemic AL (Ig light chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006;107:3489-3491.
65. Saraiva M: Sporadic cases of hereditary amyloidosis. N Engl J Med 2002;346:1818-1819.
66. Gallo GR, Feiner HD, Chuba JV, et al: Characterization of tissue amyloid by immunofluorescence microscopy. Clin Immunol Immunopathol 1986;39:479-490.
67. Gallo G, Picken MM, Buxbaum J, et al: Deposits in monoclonal immunoglobulin deposition disease lack amyloid P component. Mod Pathol 1988;1:453-456.
68. Yang GC, Nieto R, Stachura I, et al: Ultratstructural immunohistochemical localization of polyclonal IgG, C3, and amyloid P component on the Congo red-negative amyloid-like fibrils of fibrillary glomerulopathy. Am J Pathol 1992;141:409-419.
69. Novak L, Cook WJ, Herrera GA, et al: AL-amyloidosis is underdiagnosed in renal biopsies. Nephrol Dial Transplant 2004;19:3050-3053.
70. Picken MM, Larrondo-Lillo M, Coria F, et al: Distribution of the protease inhibitor alpha 1-antichymotrypsin in cerebral and systemic amyloid. J Neuropathol Exp Neurol 1990;49:41-48.
71. Goni F, Gallo G: Extraction and chemical characterization of tissue-deposited proteins from minute diagnostic biopsy specimens. Methods Mol Biol 2005;299:261-266.
72. Murphy CL, Eulitz M, Hrncic R, et al: Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin Pathol 2001;116:135-142.
73. Picken MM, Thulasiraman V, Picken RN, et al: Tissue detection and characterization of amyloidis proteomics the answer; in Grateau G, Kyle RA, Skinner M (eds): Amyloid and Amyloidosis. Boca Raton, London, New York, Washington DC, CRC Press, 2005, pp 27-29.
74. Omtvedt LA, Bailey D, Renouf DV, et al: Glycosylation of immunoglobulin light chains associated with amyloidosis. Amyloid 2000;7:227-244.
75. Dealwis C, Wall J: Towards understanding the structure-function relationship of human amyloid disease. Curr Drug Targets 2004;5:159-171.
76. Wall JS, Gupta V, Wilkerson M, et al: Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins. J Mol Recognit 2004;17:323-331.
77. Comenzo RL, Zhang Y, Martinez C, et al: The tropism of organ involvement in primary systemic amyloidosis: Contributions of IgVL germline gene use and clonal plasma cell burden. Blood 2004;98:714-720.
78. Herrera GA, Russell WJ, Isaac J, et al: Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangipathic findings documented in vivo. Ultrastruct Pathol 1999;23:107-126.
79. Trinkaus-Randall V, Walsh MT, Stevees S, et al: Cellular response of cardiac fibroblasts to amyloidogenic light chains. Am J Pathol 2005;166:197-208.
80. Keeling J, Teng J, Herrera GA: AL-amyloidosis and light chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest 2004;84:1322-1338.
81. Teng J, Russell WJ, Gu X, et al: Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 2004;84:440-451.
82. Abraham RS, Geyer SM, Price-Troska TL, et al: Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 2003;101:3801-3808.
83. Alexandrescu AT: Amyloid accomplices and enforcers. Protein Sci 2005;14:1-12.
84. Kisilevsky R: Amyloidosis in vivo: from molecular interactions to therapeutic targets; in Grateau G, Kyle RA, Skinner M (eds): Amyloid and Amyloidosis. Boca Raton, London, New York, Washington DC, CRC Press, 2005, pp 6-8.
85. Hazenberg BP, van Rijswijk MH, Piers DA, et al: Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006;119(355):e15-e24.